Cargando…

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance

Aim: The main goal of this study was to elucidate at the transcript level the tyrosine kinase expression profiles of primary leukemia cells from mixed lineage leukemia 1 gene rearranged (KMT2A/MLL-R(+)) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Methods: We evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uckun, Fatih M., Qazi, Sanjive
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771742/ https://www.ncbi.nlm.nih.gov/pubmed/36627892 http://dx.doi.org/10.20517/cdr.2022.78

Ejemplares similares

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements
por: Esposito, Maria Teresa, et al.
Publicado: (2022)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia
por: de Groot, Anne P., et al.
Publicado: (2021)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
por: Nimmagadda, S C, et al.
Publicado: (2018)

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up
por: Uckun, Fatih M., et al.
Publicado: (2019)

Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
por: Rabello, Doralina do Amaral, et al.
Publicado: (2018)

High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma
por: Uckun, Fatih M., et al.
Publicado: (2023)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

RNA binding proteins in MLL-rearranged leukemia
por: Tran, Tiffany M., et al.
Publicado: (2022)

Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
por: Banday, Shahid, et al.
Publicado: (2020)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
por: Winters, Amanda C., et al.
Publicado: (2017)

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
por: Zangrando, Andrea, et al.
Publicado: (2009)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies
por: Uckun, Fatih M., et al.
Publicado: (2014)

Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients
por: Uckun, Fatih M., et al.
Publicado: (2013)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
por: Lopez-Millan, Belen, et al.
Publicado: (2019)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
por: Feng, Zizhen, et al.
Publicado: (2016)

ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia
por: Wang, Yungui, et al.
Publicado: (2017)

Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia
por: Fischer, Jacqueline, et al.
Publicado: (2023)

The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia
por: Esposito, Maria Teresa
Publicado: (2019)

Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways
por: Qu, Mei, et al.
Publicado: (2021)

Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)

A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator()
por: Uckun, Fatih M., et al.
Publicado: (2014)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_90vej2aukjel07evdu8vq485eu